Abstract
The emergence of novel SARS coronavirus 2 (SARS-CoV-2) in 2019 has triggered an ongoing global pandemic of severe pneumonia-like disease designated as coronavirus disease 2019 (COVID-19). To date, more than 2.1 million confirmed cases and 139,500 deaths have been reported worldwide, and there are currently no medical countermeasures available to prevent or treat the disease. As the development of a vaccine could require at least 12-18 months, and the typical timeline from hit finding to drug registration of an antiviral is >10 years, repositioning of known drugs can significantly accelerate the development and deployment of therapies for COVID-19. To identify therapeutics that can be repurposed as SARS-CoV-2 antivirals, we profiled a library of known drugs encompassing approximately 12,000 clinical-stage or FDA-approved small molecules. Here, we report the identification of 30 known drugs that inhibit viral replication. Of these, six were characterized for cellular dose-activity relationships, and showed effective concentrations likely to be commensurate with therapeutic doses in patients. These include the PIKfyve kinase inhibitor Apilimod, cysteine protease inhibitors MDL-28170, Z LVG CHN2, VBY-825, and ONO 5334, and the CCR1...Continue Reading
Citations
May 27, 2020·Pharmaceutical Research·Nancy BakerSean Ekins
Aug 2, 2020·Journal of Translational Medicine·Darawan RinchaiDamien Chaussabel
Oct 1, 2020·Viruses·Emily E Ackerman, Jason E Shoemaker
Sep 13, 2020·Viruses·Philip L TzouRobert W Shafer
Oct 7, 2020·HSS Journal : the Musculoskeletal Journal of Hospital for Special Surgery·Meghan A KirkseyAndy O Miller
Nov 10, 2020·Nucleic Acids Research·Dmitry TworowskiMilana Frenkel-Morgenstern
Jan 14, 2021·The Biochemical Journal·George M Burslem
May 25, 2020·The Protein Journal·Francis K Yoshimoto
Feb 5, 2021·Journal of Medicinal Chemistry·Rinky Raghuvanshi, Sandip B Bharate
Jan 19, 2021·3 Biotech·Naun Lobo-GaloEduardo Ruiz-Bustos
Nov 19, 2020·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Madeleine Ennis, Katerina Tiligada
Oct 30, 2020·Nature Reviews. Microbiology·Philip V'kovskiVolker Thiel
Dec 29, 2020·Physiological Reports·Kirk P Conrad
Feb 25, 2021·Nature Biotechnology·Ruili HuangWei Zheng
Mar 26, 2021·Scientific Reports·Hu ZhuRuili Huang
Mar 12, 2021·Frontiers in Pharmacology·Luca PinziGiulio Rastelli
Jun 3, 2021·Biomolecules·Mathew A CobanThomas R Caulfield
Jun 11, 2020·ACS Nano·Carsten WeissLucia Gemma Delogu
Sep 2, 2021·International Journal of Nanomedicine·Ashagrachew Tewabe YayehradAbyou Seyfu Ambaye